GBT to Review Candidate Data for Sickle Cell on June 10 Webcast

GBT to Review Candidate Data for Sickle Cell on June 10 Webcast

Global Blood Therapeutics, a biopharma focused on the development of innovative therapeutics for the treatment of blood-based disorders such as sickle cell disease (SCD), will host an investor’s webcast at 1:30 p.m. June 10.

The event will feature members of GBT’s management team and experts during a review of GBT440 data to be presented at the European Hematology Association’s (EHA) 21st Congress June 9-12 in Copenhagen, Denmark.

According to a press release, participants in the review process include Dr. H. Franklin Bunn from Harvard Medical School and Brigham and Women’s Hospital; Dr. Paul Telfer, of Barts Health NHS Trust and Queen Mary, from the University of London; and Dr. Wally R. Smith, from Virginia Commonwealth University.

GBT440 is a lead drug candidate of the biopharma. It is an oral, once-daily therapy for SCD. The candidate is currently under evaluation in healthy subjects and SCD patients in a randomized, placebo-controlled, double-blind Phase 1/2 clinical trial, “A Study of the Safety, Blood Levels and Biological Effects of GBT440 in Healthy Subjects and Subjects With Sickle Cell Disease.”

The GBT presentations at EHA 2016 will review data from this ongoing Phase 1/2 study, including 90-day data from a group of patients taking 700 mg of GBT440, 28-day results from three dosing groups of GBT440 and further data on pharmacokinetics and pharmacodynamics of the lead drug candidate.

SCD describes many inherited red blood cell disorders. People with SCC have abnormal levels of hemoglobin S, or sickle hemoglobin, which is a protein in red blood cells that carries oxygen across the body.

SCD is a genetic disease and not contagious. People with SCD inherit two abnormal genes, one from each parent. In all forms of SCD, at least one of the two abnormal genes triggers a person’s body to produce hemoglobin S. When one has two hemoglobin S genes, hemoglobin SS, the disease is called sickle cell anemia – the most common and severe kind of SCD. As a result, red blood cells have an abnormal shape that causes these cells to obstruct blood vessels, resulting in pain, tissue damage, and insufficient oxygenation of certain tissues.

To watch the presentations on the live webcast, visit the the Investors & Media section of GBT’s website at www.globalbloodtx.com.

Leave a Comment

Your email address will not be published. Required fields are marked *